Results 11 to 20 of about 3,446,938 (405)

Airway microbiota in severe asthma and relationship to asthma severity and phenotypes [PDF]

PLOS ONE, 2016
BACKGROUND:The lower airways harbor a community of bacterial species which is altered in asthma. OBJECTIVES:We examined whether the lower airway microbiota were related to measures of asthma severity.
Bhavsar, P, Brinkmann, F, Cardenas, PA, Chung, KF, Cookson, W, Cox, M, Duff, R, Liang, Z, Moffatt, M, Zhang, Q   +9 more
core   +17 more sources

Allergy in severe asthma [PDF]

Allergy, 2017
It is well recognized that atopic sensitisation is an important risk factor for asthma, both in adults and in children. However, the role of allergy in severe asthma is still under debate. The term "Severe Asthma" encompasses a highly heterogeneous group
Bakirtas, Arzu, Bel, Elizabeth, Bjermer, Leif, Custovic, Adnan, DEL GIACCO, STEFANO, Diamant, Zuzana, Hamelmann, Eckard, Heffler, Enrico, Kalayci, Ömer, Saglani, Sejal, Sergejeva, Svetlana, Seys, Sven, Simpson, Angela   +12 more
core   +10 more sources

Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry

European Respiratory Journal, 2023
Background Novel biologic therapies have revolutionised the management of severe asthma with more ambitious treatment aims. Here we analyse the definition of clinical remission as a suggested treatment goal and consider the characteristics associated ...
P. McDowell, Ronald McDowell, John Busby, M. Eastwood, P. Patel, David J. Jackson, Adel Mansur, M. Patel, Hassan Burhan, Simon Doe, Rekha Chaudhuri, Robin Gore, James W. Dodd, Deepak Subramanian, Thomas Brown, L. Heaney, Chiesi. L.G. Heaney   +16 more
semanticscholar   +1 more source

Biologics and airway remodeling in severe asthma

Allergy. European Journal of Allergy and Clinical Immunology, 2022
Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in part can become irreversible to conventional therapies, defining the concept of airway remodeling.
G. Varricchi, S. Ferri, J. Pepys, R. Poto, G. Spadaro, E. Nappi, G. Paoletti, J. C. Virchow, E. Heffler, W. Canonica   +9 more
semanticscholar   +1 more source

Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

Journal of Asthma and Allergy, 2022
Introduction International registries provide opportunities to describe use of biologics for treating severe asthma in current clinical practice.
A. Menzies-Gow, C. McBrien, B. Unni, C. Porsbjerg, M. Al‐Ahmad, C. Ambrose, K. Dahl Assing, A. von Bülow, J. Busby, B. Cosío, J. FitzGerald, E. Garcia Gil, S. Hansen, Liam G aHeaney, M. Hew, D. Jackson, M. Kallieri, S. Loukides, N. Lugogo, A. Papaioannou, D. Larenas-Linnemann, W. Moore, L. Perez-de-Llano, L. Rasmussen, J. Schmid, Salman Siddiqui, M. Alacqua, T. Tran, C. Suppli Ulrik, J. Upham, E. Wang, L. Bulathsinhala, V. Carter, I. Chaudhry, N. Eleangovan, R. Murray, C. Price, D. Price   +37 more
semanticscholar   +1 more source

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.

New England Journal of Medicine, 2021
BACKGROUND Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new monoclonal antibody against the upstream alarmin interleukin-33.
M. Wechsler, M. K. Ruddy, I. Pavord, E. Israel, K. Rabe, L. Ford, J. Maspero, R. Abdulai, Chih-Chi Hu, R. Martincova, A. Jessel, M. Nivens, N. Amin, D. Weinreich, G. Yancopoulos, H. Goulaouic   +15 more
semanticscholar   +1 more source

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.

New England Journal of Medicine, 2021
BACKGROUND Children with moderate-to-severe asthma continue to have disease complications despite the receipt of standard-of-care therapy. The monoclonal antibody dupilumab has been approved for the treatment of adults and adolescents with asthma as well
L. Bacharier, J. Maspero, C. Katelaris, A. Fiocchi, R. Gagnon, I. de Mir, N. Jain, L. Sher, X. Mao, Dongfang Liu, Yi Zhang, Asif H Khan, U. Kapoor, F. Khokhar, P. Rowe, Y. Deniz, M. Ruddy, E. Laws, N. Patel, D. Weinreich, G. Yancopoulos, N. Amin, L. Mannent, D. Lederer, M. Hardin   +24 more
semanticscholar   +1 more source

Asthma heterogeneity and severity [PDF]

World Allergy Organization Journal, 2016
Asthma is a common, chronic inflammatory airways disease characterized by a clinical syndrome of bronchial hyperresponsiveness, inflammation, and reversible airflow obstruction. Individuals with asthma can vary widely in clinical presentation, severity, and pathobiology.
Tara F. Carr, Eugene R. Bleecker
openaire   +4 more sources

Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial.

New England Journal of Medicine, 2021
BACKGROUND Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear ...
C. Brightling, Parameswaran Nair, D. Cousins, R. Louis, Dave Singh   +4 more
semanticscholar   +1 more source

Severe asthma in children [PDF]

Respirology, 2017
ABSTRACT Most children with asthma have their disease easily controlled if low‐dose inhaled corticosteroids (ICSs) are regularly and correctly administered. If a child presents with asthma which is apparently resistant to therapy with high‐dose ICS and other controllers, then they have problematic severe asthma.
Andrew Bush, Louise Fleming, Sejal Saglani   +2 more
openaire   +8 more sources